GARY GOLDBERG

Dr. GARY GOLDBERG

Molecular Biology, Rowan University, B307 Science Center, 2 Medical Center Dr., Stratfod, NJ 08084, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2018 in Cancer Science
Verified
Journal Article
Open access
PDF file
HKHarini Krishnan
Harini Krishnan
JRJulie Rayes
Julie Rayes
TMTomoyuki Miyashita
Tomoyuki Miyashita
GIGenichiro Ishii
Genichiro Ishii
EREdward P. Retzbach
Edward P. Retzbach
GGGARY GOLDBERG
GARY GOLDBERG
Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma.

10 March 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
JOJhon A. Ochoa-Alvarez
Jhon A. Ochoa-Alvarez
HKHarini Krishnan
Harini Krishnan
JPJohn G. Pastorino
John G. Pastorino
ENEvan Nevel
Evan Nevel
DKDavid Kephart
David Kephart
GGGARY GOLDBERG
GARY GOLDBERG
Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms

16 April 2008 in Cancer Science
Verified
Journal Article
Open access
PDF file
XLXun Li
Xun Li
ZJZhenyu Jia
Zhenyu Jia
YSYongquan Shen
Yongquan Shen
HIHitoshi Ichikawa
Hitoshi Ichikawa
JJJonathan Jarvik
Jonathan Jarvik
GGGARY GOLDBERG
GARY GOLDBERG
The Src tyrosine kinase associates with the focal adhesion adaptor protein Cas (Crk‐associated substrate) to suppress the expression of potential tumor suppressor genes. For example, Src utilizes Cas to suppress the expression of the LIM‐only protein Fhl1 (four and a half LIM domains 1), in order to promote non‐anchored tumor‐cell growth and migration. Here, we report that the promoter region of the Fhl1 gene was methylated more in Src‐transformed cells than non‐transformed cells. In addition, global expression analysis indicates that Fhl1 induced expression of serum deprivation response factor (Sdpr) in Src‐transformed cells. Moreover, Fhl1 and Sdpr was expressed in approximately 87% and 40% of samples obtained from non‐transformed breast, 100% of samples obtained from non‐transformed kidney, and over 60% of samples obtained from non‐transformed prostate. In contrast, Fhl1 and Sdpr was detected in approximately 40% and 7% of matched samples from mammary carcinoma, less than 11% of matched samples from kidney carcinoma, and in less than 22% of matched samples from prostate carcinoma. These data indicate that Fhl1 and Sdpr expression was significantly reduced in tumors of the breast (P < 0.02 and P < 0.001), kidney (P < 0.01), and prostate (P < 0.05). In addition, although Src can activate mitogen‐activated protein kinase (MAPK) to promote tumor‐cell growth, our data indicate that Src did not rely on MAPK activity to suppress the expression of Fhl1 and Sdpr in transformed cells. Thus, Src induced methylation of the promoter region of the Fhl1 gene; Src suppressed Fhl1 and Sdpr expression independent of mitogen‐activated protein kinase (MAPK) activity; Fhl1 induced the expression of Sdpr in Src‐transformed cells; and Fhl1 and Sdpr expression was suppressed in tumors of the breast, kidney, and prostate. (Cancer Sci 2008; 99: 1326–1333)

1 March 2018 in Oral Oncology
Verified
Journal Article
Closed access
EREdward P. Retzbach
Edward P. Retzbach
SSStephanie A. Sheehan
Stephanie A. Sheehan
ENEvan M. Nevel
Evan M. Nevel
ABAmber Batra
Amber Batra
TPTran Phi
Tran Phi
GGGARY GOLDBERG
GARY GOLDBERG

1 January 2017 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
KGKarina H. Goldberg
Karina H. Goldberg
AYAriel C. Yin
Ariel C. Yin
AMArchana Mupparapu
Archana Mupparapu
EREdward P. Retzbach
Edward P. Retzbach
GGGARY GOLDBERG
GARY GOLDBERG
CYCatherine F. Yang
Catherine F. Yang
Skin cancer is extremely common, and melanoma causes about 80% of skin cancer deaths. In fact, melanoma kills over 50 thousand people around the world each year, and these numbers are rising. Clearly, standard treatments are not effectively treating melanoma, and alternative therapies are needed to address this problem. Hibiscus tea has been noted to have medicinal properties, including anticancer effects. Extracts from Hibiscus have been shown to inhibit the growth of a variety of cancer cells. In particular, recent studies found that polyphenols extracted from Hibiscus sabdariffa by organic solvents can inhibit melanoma cell growth. However, effects of aqueous extracts from Hibiscus rosa-sinesis flowers, which are commonly used to make traditional medicinal beverages, have not been examined on melanoma cells. Here, we report that aqueous H. rosa-sinesis flower extract contains compounds that inhibit melanoma cell growth in a dose dependent manner at concentrations that did not affect the growth of nontransformed cells. In addition, these extracts contain low molecular weight growth inhibitory compounds below 3 kD in size that combine with larger compounds to more effectively inhibit melanoma cell growth. Future work should identify these compounds, and evaluate their potential to prevent and treat melanoma and other cancers.

1 January 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
HKHarini Krishnan
Harini Krishnan
WMW. Todd Miller
W. Todd Miller
FBFrancisco Blanco
Francisco Blanco
GGGARY GOLDBERG
GARY GOLDBERG